This article is more than 5 years old. Information may no longer be current.

Aerie reports net loss of $22.7 million in first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerie Pharmaceuticals reported a GAAP net loss of $22.7 million, or $0.85 per share, in the first quarter compared with a GAAP net loss of $17.2 million, or $0.70 per share, in the same quarter of 2015, according to a press release.

Operating expenses were reported at $22.1 million in the first quarter, which included $12.3 million in research and development expenses and $9.8 million in general and administrative expenses.

Cash, cash equivalents and investments were reported at $130.8 million as of March 31.